Notice of MaineCare Reimbursement Methodology Change: MaineCare Benefits Manual, Section 67, Nursing Facility Services

Notice of MaineCare Reimbursement Methodology Change

AGENCY:  Department of Health and Human Services, Office of MaineCare Services

SERVICES INCLUDED:  Chapter 101, MaineCare Benefits Manual, Section 67, Nursing Facility Services

NATURE OF PROPOSED CHANGES: The Department plans to submit a State Plan Amendment in the near future identifying the following:

Commissioner Lambrew Appears Before Government Oversight Committee

Joined by Acting Child and Family Services Director Bobbi Johnson

Health and Human Services Commissioner Jeanne Lambrew appeared before the Government Oversight Committee today to provide testimony on the child welfare system. She was joined by Bobbi Johnson, Acting Director of the Office of Child and Family Services.

The remarks of Commissioner Lambrew and Acting Director Johnson, as prepared for delivery, are below.


Commissioner Lambrew:

10-144 C.M.R. Ch. 333; Low Cost Drugs for the Elderly and Disabled (DEL) Manual; MC Rule #305P - DEL Asset Test Removal

The proposed rule change would remove the asset test, Section 2.1, effective retroactive to January 1, 2024. The proposed rule change is based on a legislative change to 22 M.R.S. § 254-D(4)(B) made by P.L. 2023, ch. 412, Part EEEEE. This rule change is consistent with a recent MaineCare Eligibility Manual proposed rule change which would remove the asset test for all Medicare Savings Plan coverage types. Retroactive rulemaking is permissible under 22 M.R.S.

MaineCare Notice of Agency Rule-making Adoption, MaineCare Benefits Manual, Chapter II, Section 89

Notice of Agency Rule-making Adoption

AGENCY: Department of Health and Human Services, MaineCare Services

CHAPTER NUMBER AND TITLE: 10-144 C.M.R. Chapter 101, MaineCare Benefits Manual, Chapter II, Section 89, MaineMOM Services and Reimbursement

ADOPTED RULE NUMBER:

CONCISE SUMMARY:  

COVID-19 Therapeutics Transition to Commercial Market, and UPDATE on COVID-19 Vaccine Coverage

In a letter released October 27, 2023, the U.S. Department of Health and Human Services (HHS) announced the plan to transition two COVID-19 oral therapeutics from government supplied to the commercial market. The transition process started on November 1, 2023, for Paxlovid manufactured by Pfizer and Lagevrio, manufactured by Merck.  

Subscribe to